LipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:LPDX
- CUSIP: 53630M10
- Web: N/A
- Trailing P/E Ratio:
- Foreward P/E Ratio: -6.24
- P/E Growth:
Frequently Asked Questions for LipoScience (NASDAQ:LPDX)
What is LipoScience's stock symbol?
LipoScience trades on the NASDAQ under the ticker symbol "LPDX."
How were LipoScience's earnings last quarter?
LipoScience Inc (NASDAQ:LPDX) posted its earnings results on Wednesday, November, 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. The business had revenue of $8.56 million for the quarter, compared to the consensus estimate of $8.80 million. During the same quarter last year, the firm earned ($0.31) EPS. View LipoScience's Earnings History.
Who are some of LipoScience's key competitors?
Some companies that are related to LipoScience include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), VBI Vaccines (VBIV), Mirati Therapeutics (MRTX), ContraFect Corporation (CFRX), XOMA Corporation (XOMA), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY) and Cubist Pharmaceuticals (CBST).
How do I buy LipoScience stock?
Shares of LipoScience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LipoScience's stock price today?
MarketBeat Community Rating for LipoScience (NASDAQ LPDX)MarketBeat's community ratings are surveys of what our community members think about LipoScience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of LipoScience stock can currently be purchased for approximately $5.24.
Consensus Ratings for LipoScience (NASDAQ:LPDX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for LipoScience (NASDAQ:LPDX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for LipoScience (NASDAQ:LPDX)Earnings History by Quarter for LipoScience (NASDAQ LPDX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/12/2014||Q3 14||($0.26)||($0.28)||$8.80 million||$8.56 million||View||N/A|
|8/12/2014||Q2 2014||($0.24)||($0.27)||$8.90 million||$9.05 million||View||N/A|
|5/12/2014||Q1 14||($0.19)||($0.13)||$12.25 million||$12.01 million||View||N/A|
|3/10/2014||Q413||($0.24)||($0.17)||$12.71 million||$12.72 million||View||N/A|
Earnings Estimates for LipoScience (NASDAQ:LPDX)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS
Dividend History for LipoScience (NASDAQ:LPDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for LipoScience (NASDAQ:LPDX)Insider Trades by Quarter for LipoScience (NASDAQ:LPDX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/4/2013||Daniel Levangie||Director||Buy||10,000||$4.17||$41,700.00|| |
|12/4/2013||E. Duffy Mcdonald||VP||Sell||12,731||$4.07||$51,815.17|| |
|11/25/2013||James Hurley||Director||Buy||5,100||$3.91||$19,941.00|| |
|11/18/2013||Robert Greczyn, Jr.||CEO||Buy||10,000||$4.15||$41,500.00|| |
|1/30/2013||Buzz Benson||Director||Buy||50,000||$9.00||$450,000.00|| |
|1/30/2013||Three Arch Capital Lp||Major Shareholder||Buy||215,000||$9.00||$1,935,000.00|| |
Headline Trends for LipoScience (NASDAQ:LPDX)
Latest Headlines for LipoScience (NASDAQ:LPDX)
LipoScience (LPDX) Chart for Friday, July, 21, 2017